Longitudinal clinical findings and outcome among patients with cryptococcus gattii infection in British Columbia

Clinical Infectious Diseases

Volumn 60, Issue 9, 2015, Pages 1368-1376

  Phillips, Peter ^a,b,c   Galanis, Eleni ^b   Macdougall, Laura ^b   Chong, Mei Y ^b   Balshaw, Robert ^b   Cook, Victoria J ^b   Bowie, William ^b,c   Steiner, Theodore ^b,c   Hoang, Linda ^b   Morshed, Muhammad ^b   Ghesquiere, Wayne ^b,d   Forrest, David M ^b,e   Roscoe, Diane ^b,c   Doyle, Patrick ^b,c   Kibsey, Pamela C ^b,f   Connolly, Thomas ^b,d   Mirzanejad, Yazdan ^b,g   Thompson, Darby ^b   Saliken, John ^g   Sanders, Bruce ^g   Partlow, Eric ^g   Vortel, Jerry ^g   Arikan, Yasmin ^g   Fyfe, Murray ^g   more..

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c VANCOUVER GENERAL HOSPITAL   (Canada)

^d Royal Jubilee Hospital   (Canada)

^e Nanaimo Regional General Hospital   (Canada)

^f Department of Microbiology ^*  (Canada)

^g SURREY MEMORIAL HOSPITAL   (Canada)

Author keywords

Cryptococcal antigen; Cryptococcomas; Cryptococcosis; Cryptococcus gattii

Indexed keywords

ANTIFUNGAL AGENT; FUNGUS ANTIGEN;

ADOLESCENT; ADULT; AGED; ARTICLE; ASYMPTOMATIC DISEASE; CANADA; CENTRAL NERVOUS SYSTEM INFECTION; CHILD; CLINICAL FEATURE; CRYPTOCOCCOSIS; CRYPTOCOCCUS GATTII; CRYPTOCOCCUS GATTII INFECTION; FEMALE; FOLLOW UP; HUMAN; IMMUNOCOMPROMISED PATIENT; LONGITUDINAL STUDY; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME; BLOOD; BRITISH COLUMBIA; ISOLATION AND PURIFICATION; LUNG; LUNG DISEASES, FUNGAL; MICROBIOLOGY; MIDDLE AGED; MORTALITY; PARASITOLOGY; PATHOGENICITY; PRESCHOOL CHILD; RADIOGRAPHY; RECURRENT DISEASE; REGRESSION ANALYSIS; TIME FACTOR; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, FUNGAL; BRITISH COLUMBIA; CHILD; CHILD, PRESCHOOL; CRYPTOCOCCOSIS; CRYPTOCOCCUS GATTII; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; LONGITUDINAL STUDIES; LUNG; LUNG DISEASES, FUNGAL; MALE; MIDDLE AGED; RECURRENCE; REGRESSION ANALYSIS; RISK FACTORS; TIME FACTORS; YOUNG ADULT;

EID: 84928889195     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ041     Document Type: Article

References (21)

1. Sorrell TC, Chen SC, Phillips P, Marr KA. Clinical perspectives on Cryp-tococcus neoformans and Cryptococcus gattii: implications for diagnosis and management. In: Heitman J, Kozel TR, Kwon-Chung KJ, Perfect JR, Casadevall A, eds. Cryptococcus: from human pathogen to model yeast. Washington, DC: ASM Press, 2011:595-606.
2. MacDougall L, Kidd SE, Galanis E, et al. Spread of Cryptococcus gattii in British Columbia, Canada, and detection in the Pacific Northwest, USA. Emerg Infect Dis 2007; 13:42-50.
3. DeBess E, Cieslak PR, Marsden-Haug N, et al. Emergence of Cryptococ-cus gattii-Pacific Northwest, 2004-2010. MMWR Morb Mortal Wkly Rep 2010; 59:865-8.
4. British Columbia Centre for Disease Control. BC annual summary of reportable diseases, 2012. Available at: http://www.bccdc.ca/dis-cond/a-z/-c/CryptococcusGattii/Cryptococcus+gattii.htm. Accessed 1 October 2013.
5. Galanis E, MacDougall L, Kidd S, Morshed M; BC Cryptococcus gattii Working Group. Epidemiology of Cryptococcus gattii, British Columbia, Canada, 1999-2007. Emerg Infect Dis 2010; 16:251-7.
6. MacDougall L, Fyfe M, Romney M, Starr M, Galanis E. Risk factors for Cryptococcus gattii infection, British Columbia, Canada. Emerg Infect Dis 2011; 17:193-9.
7. Mitchell DH, Sorrell TC, Allworth AM, et al. Cryptococcal disease of the CNS in immunocompetent hosts: influence of cryptococcal variety on clinical manifestations and outcome. Clin Infect Dis 1995; 20:611-6.
8. Harris JR, Lockhart SR, Debess E, et al. Cryptococcus gattii in the United States: clinical aspects of infection with an emerging pathogen. Clin Infect Dis 2011; 53:1188-95.
9. Chen SC-A, Slavin MA, Heath CH, et al. Clinical manifestations of Cryptococcus gattii infection: determinants of neurological sequelae and death. Clin Infect Dis 2012; 55:789-98.
10. Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Infect Dis Soc Am. Clin Infect Dis 2000; 30:710-8.
11. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010; 50:291-322.
12. Chen SC-A, Korman TM, Slavin MA. Antifungal therapy and management of complications of cryptococcosis due to Cryptococcus gattii. Clin Infect Dis 2013; 57:543-51.
13. Smith RM, Mba-Jonas A, Tourdjman M, et al. Treatment and outcomes among patients with Cryptococcus gattii infections in the United States Pacific Northwest. PLoS One 2014; 9:e88875.
14. Kidd S, Hagen F, Tscharke R, et al. A rare genotype of Cryptococcus gat-tii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). Proc Natl Acad Sci USA 2004; 101:17258-63.
15. Powderly WG, Cloud GA, Dismukes WE, Saag MS. Measurement of cryptococcal antigen in serum and cerebrospinal fluid: value in the management of AIDS-associated cryptococcal meningitis. Clin Infect Dis 1994; 18:789-92.
16. Hospenthal DR, Bennett JE. Persistence of cryptococcomas on neuro-imaging. Clin Infect Dis 2000; 31:1303-6.
17. Yu JQ, Tang KJ, Xu BL, Xie CM, Light RW. Pulmonary cryptococcosis in non-AIDS patients. Braz J Infect Dis 2012; 16:531-9.
18. Ye F, Xie JX, Zeng QS, Chen GQ, Zhong SQ, Zhong NS. Retrospective analysis of 76 immunocompetent patients with primary pulmonary cryptococcosis. Lung 2012; 190:339-46.
19. Chang WC, Tzao C, Hsu HH, et al. Pulmonary cryptococcosis: comparison of clinical and radiographic characteristics in immunocompetent and immunocompromised patients. Chest 2006; 129:333-40.
20. Nadrous HF, Antonios VS, Terrell CL, Ryu JH. Pulmonary cryptococ-cosis in nonimmunocompromised patients. Chest 2003; 124:2143-7.
21. Fyfe M, MacDougall L, Romney M, et al. Cryptococcus gattii infections on Vancouver Island, British Columbia, Canada: emergence of a tropical fungus in a temperate environment. Can Commun Dis Rep 2008; 34:1-12.